FDA Office of Hematology and Oncology Products is now Office of Oncologic Diseases
from The Cancer Letter
The Office of Hematology and Oncology Products at FDA has been renamed the Office of Oncologic Diseases — a move that includes an internal reorganization of divisions, as part of modernization plans approved in September 2019. "The name change reflects the emphasis on oncology and malignant hematology, with the move of non-malignant hematology to a new division," said Richard Pazdur, acting director of OOD and director of the FDA's Oncology Center of Excellence.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063